The development of a selective CDK7 inhibitor with anti-tumor activity

被引：0
|
作者：
Coombes, Raoul
Cheiper
Jogalekar, Ashutosh S.
Brackow, Jan
Ali, Simak
Heathcote, Dean
Kroll, Sebastian
Bodo, S.
Siwicka, Aleksandra
Periyasamy, Manikandan
Tolhurst, Robert
Kanneganti, Seshu
Snyder, James
Liotta, Dennis
Aboagye, Eric
Barrett, Anthony
机构：
[1] Univ London Imperial Coll Sci Technol & Med, London, England
[2] Emory Univ, Atlanta, GA 30322 USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3311
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Potent anti-tumor activity of AUR102, a selective covalent inhibitor of CDK7
    Satyam, L. K.
    Poddutoori, R.
    Thiyagarajan, S.
    Mukherjee, S.
    Kaza, L. N.
    Charamanna, K.
    Marappan, S.
    Samiulla, D.
    Tiwari, N. K.
    Devaraja, T.
    Aravind, A.
    Dhudashiya, A. A.
    Booher, R.
    Daginakatte, G.
    Antony, T.
    Chelur, S.
    Nellore, K.
    Giri, S.
    Ramachandra, M.
    Samajdar, S.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S47 - S47
  • [2] SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo
    Hu, Shanhu
    Marineau, Jason
    Hamman, Kristin
    Bradley, Michael
    Savinainen, Anneli
    Alnemy, Sydney
    Rajagopal, Nisha
    Orlando, David
    Chuaqui, Claudio
    Olson, Eric
    CANCER RESEARCH, 2019, 79 (13)
  • [3] An oral and selective CDK7 inhibitor demonstrates substantial anti-tumor effect in breast and ovarian cancer models
    Hu, S.
    Marineau, J.
    Bradley, M.
    Hamman, K.
    Alnemy, S.
    Smith, D.
    Carulli, J.
    Chuaqui, C.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E39 - E40
  • [4] SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors
    Hu, Shanhu
    Ke, Nan
    Ren, Yixuan
    Miljovska, Sofija
    Rajagopal, Nisha
    McKeown, Michael
    Orlando, David
    Sprott, Kevin
    Choi, Yoon J.
    Olson, Eric
    Fritz, Christian C.
    CANCER RESEARCH, 2017, 77
  • [5] Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma
    Gao, Yang
    Volegova, Marina
    Nasholm, Nicole
    Das, Sanjukta
    Kwiatkowski, Nicholas
    Abraham, Brian J.
    Zhang, Tinghu
    Gray, Nathanael S.
    Gustafson, Clay
    Krajewska, Malgorzata
    George, Rani E.
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [6] Olomoucine derived synthetic CDK inhibitors: Selective induction of apoptotic death in tumor cells and in vivo anti-tumor activity are mediated via direct inhibition of cdk7
    Hajduch, M
    Noskova, V
    Havlieek, L
    Feketova, G
    Gojova, L
    Krystof, V
    Vesely, J
    Strnad, M
    Mihal, V
    ANNALS OF ONCOLOGY, 1998, 9 : 136 - 136
  • [7] Q901; a highly selective covalent cdk7 inhibitor inducing substantial anti-tumor effect in a broad spectrum of solid tumor lineages
    Yu, Donghoon
    Jeon, Yeejin
    Lee, Seung-Joo
    Kim, Jaeseung
    Nam, Kiyean
    CANCER RESEARCH, 2022, 82 (12)
  • [8] Functional dissection of CDK7 in transcription using a highly selective CDK7 inhibitor Q901
    Jung, Hyerim
    Um, Dahun
    Lee, Yoonji
    Yu, Donghoon
    Lee, Dayoung
    Ahn, Jiye
    Kim, Jeongjun
    Lee, Seung-Joo
    Kim, Jaeseung
    Nam, Kiyean
    Kim, Tae-Kyung
    CANCER RESEARCH, 2024, 84 (06)
  • [9] An oral and selective CDK12 inhibitor demonstrates robust anti-tumor activity.
    Hu, Shanhu
    Moebius, David
    Dworakowski, Wojciech
    Cooper, Elliott
    LaPlaca, Derek
    Alnemy, Sydney
    Perera, Phone
    Marineau, Jason
    Chuaqui, Claudio
    Carulli, John P.
    Olson, Eric
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Development of TGN-1076, a selective and reversible small molecule inhibitor of CDK7
    Thode, Trason
    Li, Zhaoliang
    Weston, Alexis
    Dana, Srikanta
    Ampanattu, Sherin Daniel
    Soldi, Raffaella
    Kaadige, Mohan Rao
    Vankayalapti, Hariprasad
    Chung, Vincent
    Chao, Joseph
    Von Hoff, Daniel D.
    Sharma, Sunil
    CANCER RESEARCH, 2020, 80 (16)
12345